Document:

Exhibit 10.33

 

AMENDMENT No. 5 TO LICENSING AND
DISTRIBUTION AGREEMENT

 

This Amendment
No. 5 to LICENSING AND DISTRIBUTION AGREEMENT (this “Amendment No. 5”) is dated as of December
31, 2014 by and between Nuo Therapeutics, Inc. (formerly Cytomedix Inc.),
a Delaware corporation, with principal office at 207 Perry Parkway, Suite 1, Gaithersburg, MD 20877 (“Nuo” or
“Cytomedix”) and Millennia Holdings, Inc., a California
cooperation, with principal office at 3731 Wilshire Blvd., Suite 900, Los Angeles, CA 90010 (“Millennia”). Capitalized
terms used in this Amendment No. 5 shall have the meanings ascribed to them in the Agreement (as defined below).

 

RECITALS

 

		A.	Cytomedix and Millennia have entered into that certain Licensing and Distribution Agreement
dated September 10th, 2009, as amended by the following amendments: (i) Amendment to Licensing and Distribution
Agreement dated as of September 10, 2012; (ii) Amendment No. 2 to Licensing and Distribution Agreement dated as of March 10,
2013; (iii) Amendment No. 3 to Licensing and Distribution Agreement dated as of November 8, 2013; and (iv) Amendment No. 4
to Licensing and Distribution Agreement dated as of April 22, 2014 (the “Agreement”).

 

		B.	Nuo (as successor of Cytomedix) and Millennia have agreed to further amend the Agreement
in order to terminate the Agreement and allow for Nuo to transfer the exclusivity rights set forth in the Agreement from Millennia
to ROHTO Pharmaceutical Co., Ltd., a Japanese company, with its principal office at 1-8-1 Tatsumi-nishi, Ikuno-ku, Osaka 544-8666,
Japan (“RHOTO”) by Nuo entering into that certain Exclusive License
and Distribution Agreement with ROHTO dated as of December 31, 2014 (the “RHOTO/Nuo License Agreement”), which
is attached to, but is not and shall not be incorporated into this Amendment No. 5.

 

Now,
Therefore, in consideration of the foregoing, and for other good and valuable
consideration, the receipt and sufficiency of which are acknowledged, the parties intending to be legally bound agree as follows:

 

AGREEMENT

 

		1.	Termination of Agreement; Effectiveness of this Amendment
No. 5.

 

(a)           The Agreement is hereby terminated
effective as of the effective date of the RHOTO/Nuo License Agreement; provided, however, that the terms and conditions
set forth in Exhibit A to the Licensing and Distribution Agreement dated September 10th, 2009 shall not be terminated
and shall be incorporated into this Amendment No. 5 as if full set forth herein. For greater certainty, references to “the
Agreement” in this Amendment No. 5 shall not include this Amendment No. 5.

 

(b)           This Amendment No. 5 shall only
become effective as of the effective date of the RHOTO/Nuo License Agreement.

 

    	 	1	 

    	 	 	 

    

 

		2.	Continue Obligations of Millennia.

 

Millennia will provide clinical data and
support reasonably requested by Rohto to facilitate a smooth transition of the licensing and distribution relationship from Millennia
to Rohto. Millennia or Millennia Cooperation, a Japan corporation, with principal office at 17-1, Nihonbashi, Hakozaki-cho, Hakozaki
Regent Bldg., 3F, Chuo-ku, Tokyo, Japan (“MJ”) shall continue working with Rohto on the clinical studies and market
penetration for the Aurix System as contemplated by the RHOTO/Nuo License Agreement. Millennia or MJ will continue to support Rohto
with clinical data, wound care knowledge, and general market assistance.

 

		3.	Fees and Royalty to Millennia.

 

(a)           During the term of the RHOTO/Nuo
License Agreement, provided that Millennia performs its obligations pursuant to the terms of this Amendment No. 5, the following
fees shall be paid to Millennia by wire transfer within five business days after Nuo receives the corresponding payments from Rohto:

 

(i)          Fees:

 

(1)           Upon receiving a USD$3,000,000
upfront fee from Rohto, Nuo will pay Millennia a non-refundable fee of USD$1,500,000.

 

(2)           Upon receiving the USD$1,000,000
milestone fee from Rohto for achievement of NHI pricing, Nuo will pay non-refundable USD$500,000 to Millennia.

 

(3)           In the event that Rohto pays
Nuo additional fees for expansion into other Asian territories, and assuming RHOTO has complied with the performance criteria established
between Nuo and Rohto, all as contemplated by the RHOTO/Nuo License Agreement, upon Nuo’s receipt of such additional fees
from Rohto, Nuo will pay Millennia an amount equal to 50% of such additional fees.

 

(ii)         Royalty:

 

(1)           To support ongoing market and
clinical activities, Millennia will receive 10% of the royalties paid by RHOTO to Nuo under the RHOTO/Nuo License Agreement. This
amount is equal to 0.9% of the “Net Sales” (as defined in the RHOTO/Nuo License Agreement).

 

(2)           Notwithstanding anything to
the contrary in this Amendment No. 5 or in the RHOTO/Nuo License Agreement, the maximum amount of all royalties paid to Millennia
shall be USD$5,000,000 in the aggregate.

 

(b)           All of Nuo’s obligations
to make any payments under this Amendment No. 5 is subject to Nuo receiving the corresponding payments from RHOTO pursuant to the
RHOTO/Nuo License Agreement.

 

    	 	2	 

    	 	 	 

    

 

		4.	Miscellaneous.

 

(a)           Except as otherwise specifically
provided in this Amendment No. 5 or as may be otherwise agreed between the parties, each party shall each pay its respective expenses
incident to this Amendment No. 5 and the transactions contemplated hereby (including, without limitation, the fees and disbursements
of their respective counsel), and no party to this Amendment No. 5 shall have any liability for such expenses incurred by any other
party, except as may be provided for in writing.

 

(b)           Neither party may assign this
Amendment No. 5, in whole or in part, or any rights hereunder without the other party’s written consent. This Amendment No.
5 shall inure to the benefit and be binding upon the parties and their respective successors and assignees. Except as provided
in this Amendment No. 5, nothing expressed or mentioned in this Amendment No. 5 is intended or shall be construed to give any person,
other than the parties to it and their respective successors and assignees, any legal or equitable right, remedy or claim under
or with respect to this Amendment No. 5 or any of its provisions.

 

(c)           Each party acknowledges that
the remedy at law for its breach of any provisions of this Amendment No. 5 may be inadequate, and that the damages flowing from
such breach may not be susceptible to being measured in monetary terms. In the event of either party’s noncompliance or violation,
as the case may be, of certain terms, representations, covenants and conditions set forth in this Amendment No. 5, the non-breaching
party may alternatively apply to a court of competent jurisdiction for a temporary restraining order, injunctive relief, and/or
such other legal and equitable remedies as may be appropriate because the non-breaching party would have no adequate remedy at
law for such violation or noncompliance. Nothing in this paragraph will be deemed to limit a party’s remedies at law or in
equity that may be pursued or availed by it for any breach by the other party of any part of this Amendment No. 5. A party will
be entitled to recover the reasonable costs and attorneys’ fees incurred in seeking relief for any such breach, if it is
successful in doing so.

 

(d)           If any portion of this Amendment
No. 5 shall be held invalid or inoperative, then so far as is reasonable and possible, the remainder of this Amendment No. 5 shall
be considered valid and operative; and to the extent possible under applicable law, effect shall be given to the intent of the
portion held invalid or inoperative.

 

(e)           This Amendment No. 5 may not
be modified or amended except by written agreement executed by each of the parties to this Amendment No. 5. This Amendment No.
5 may be executed in a number of identical counterparts, each of which shall be deemed to be an original, but all of which constitute,
collectively, one and the same Agreement; but, in making proof of this Amendment No. 5, it shall not be necessary to produce or
account for more than one counterpart.

 

(f)           This Amendment No. 5 shall automatically
terminate upon the termination of the RHOTO/Nuo License Agreement. Millennia shall never (i) challenge the validity or ownership
of any of the Licensed Technologies by Nuo or (ii) contest the fact that Millennia’s rights under this Amendment No. 5 shall
terminate upon termination of the RHOTO/Nuo License Agreement or this Amendment No. 5.

 

    	 	3	 

    	 	 	 

    

 

(g)           Each party represents and warrants
that it has full power and authority to execute and deliver this Amendment No. 5 and that neither the execution nor the delivery
of this Amendment No. 5, nor the finalization of the transactions contemplated hereby shall violate any provision of existing law
or any existing judgment, injunction, writ, order or decree of any court or governmental authorities or other authority having
jurisdiction over it, or will result in or constitute a breach or default under any indenture, contract, other commitment or restriction
to which it is a party or by which it is bound, or shall require any consent, vote or approval which has not been taken, or at
the time of the transaction involved shall not have been given or taken.

 

(h)          The parties to this Amendment
No. 5 covenant and agree that they will execute any other and further instruments and documents which reasonably are or may become
necessary or convenient to effectuate and carry out this Amendment No. 5.

 

(i)            Except as specifically contemplated
hereby, this Amendment No. 5 (which, for greater certainty, includes the Exhibit A referenced in Section 1(a)) contains
the entire understanding between the parties and supersedes prior understandings or written or oral agreements between the parties
with respect to the subject matter of this Amendment No. 5. Each party acknowledges that the other has made no representations
or warranties to it concerning the terms, enforceability, or implications of this Amendment No. 5 and that none has provided any
inducement for the other to execute this Amendment No. 5 other than the consideration referred to herein.

 

(j)           This Amendment No. 5 and all
acts and transactions pursuant hereto and the rights and obligations of the parties shall be governed, construed and interpreted
in accordance with the laws of the State of New York, without reference to rules of conflicts or choice of laws. Any disputes or
controversies which may arise between parties in connection with this Amendment No. 5 shall be finally settled by arbitration.
Such arbitration shall be held in English, in Wilmington, Delaware, the United States, pursuant to the Commercial Arbitration Rules
of the American Arbitration Association. The decision of the arbitrator(s) shall be final and binding, and judgment on the award
rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof. The arbitrator(s) shall be authorized to
award any relief, whether legal or equitable, to the party so entitled to such relief.

 

[Remainder of this
Page Intentionally Left Blank; Signature Page Follows]

 

    	 	4	 

    	 	 	 

    

 

In
Witness Whereof, this Amendment No. 5 has been executed on the date first written.

 

	Nuo therapeutics, Inc.	 	Millennia Holdings, Inc.
	 	 	 	 	 
	By:	/s/ Martin Rosendale	 	By:	/s/ Eric Chen
	 	Martin Rosendale, CEO	 	 	Eric Chen, CEO

 

    	 	5Exhibit 10.39

 

COLLABORATION AGREEMENT

 

THIS COLLABORATION AGREEMENT (the “Agreement”),
is entered into as of March 22, 2016 (the “Signing Date”) by and between Restorix Health, Inc. (“Restorix”
), a Nevada corporation, with its principal offices at 455 Hamilton Avenue, White Plains, NY 10601, and Nuo Therapeutics, Inc.
(“Nuo”), a Delaware corporation, with its principal offices at 207A Perry Parkway, Suite 1, Gaithersburg, Maryland
20877. Restorix and Nuo may at times be referred to herein individually as a “Party” or collectively as the “Parties.”

 

WITNESSETH

 

WHEREAS, Nuo is an autologous regenerative
therapies company commercializing innovative platelet based technologies for wound care, specifically the AurixTM System,
a device for the production of an autologous biologic hematogel for use on a variety of chronic wounds;

 

WHEREAS, Nuo has engaged the Centers
for Medicare and Medicaid Services (the “CMS”) and presented evidence sufficiently in support of autologous platelet
rich plasma for CMS to issue a Decision Memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds ( “NCD”
and/or “CAG-00190R3”) that provides for coverage of Aurix under its Coverage with Evidence Development (“CED”)
program for patients with certain chronic non-healing wounds and when that patient is enrolled in one of three prospective clinical
research studies primarily consisting of patient data collection (the “Protocols”);

 

WHEREAS, Restorix is a wound management
company which has various management contracts with approximately 125 hospital outpatient wound care clinics (“RXH Partner
Hospitals”);

 

WHEREAS, on January 26, 2016 Nuo filed
a voluntary petition for reorganization under chapter 11 of the United States Bankruptcy Code, 11 U.S.C. §§101 et seq.
(the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”)
under Case No. 16-10192 (MFW);

 

WHEREAS, Nuo continues to operate as
a debtor in possession in accordance with §§1107 and 1108 of the Bankruptcy Code; and

 

WHEREAS, Nuo and Restorix wish to enter
into a collaboration agreement whereby, among other things, Restorix will be provided certain geographic exclusivity benefits over
a defined period of time for the usage of Aurix in up to thirty (30) of RXH Partner Hospitals in exchange for minimum commitments
of patients enrolled in the Protocols necessary to maintain such exclusivity, all on those terms and conditions hereinafter set
forth.

 

NOW, THEREFORE, in consideration
of the foregoing, of the mutual promises herein contained, and of other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereby agree as follows:

 

     

     

    

  

		1.	Effectiveness. Except as otherwise provided in Section 15 hereof, this Agreement shall be of no force or effect
unless and until each of the following conditions are satisfied:

 

		a.	This Agreement is signed by each Party and such Party’s counterpart is delivered to the other Party.

 

		b.	This Agreement is approved by order of the Bankruptcy Court, which is in form and substance acceptable to Restorix (the “Approval
Order”).

 

		c.	The Approval Order becomes final and non-appealable (unless such condition is waived, in writing, by Restorix).

 

The day on which all of the foregoing
conditions are first satisfied (or waived) is hereinafter referred to as the “Effective Date.”

 

		2.	Services.

 

		a.	Restorix will provide access and support as reasonably necessary and appropriate at up to thirty (30) RXH Partner Hospitals
to identify and enroll patients into the Protocols including senior executive level support and leadership to the collaboration
and its enrollment goals. The enrollment goals are specifically outlined in Exhibit A by site or by a ‘cluster’ of
sites where enrollment can be aggregated for purposes of meeting the enrollment goals. The Parties acknowledge that Exhibit A is
an output growing out of joint discussions between Nuo and Restorix and they are in agreement on its content as of the Signing
Date. The Parties shall promptly confer with respect to determining which of the RXH Partner Hospitals will participate in the
program and, once agreement is reached, the names of such hospitals shall be memorialized in a separate letter agreement signed
by the Parties.

 

		b.	Restorix will reasonably assist Nuo to correct through a query process, any patient data submitted having incomplete or inaccurate
data fields.

 

		c.	Nuo will provide:

 

		i.	clinical support services by Nuo clinical staff as reasonably agreed between Nuo and Restorix as necessary and appropriate;

 

		ii.	reasonable and necessary reimbursement support in the context of the NCD and the CED program;

 

		iii.	coverage of Institutional Review Board (IRB) fees and payment to Restorix for training costs subject to a limitation of coverage
for up to five (5) sites (on a rolling basis) until site enrollment expectations have been proven over the site’s initial
90 days at which point any IRB fees paid by Restorix directly and training costs will be reimbursed by Nuo to Restorix or the RXH
Partner Hospital as appropriate; and

 

    	 	2	 

     

    

  

		iv.	community focused public relations materials for participating RXH Partner Hospitals to promote the use of Aurix and participation
in the Protocols.

 

		d.	The Parties agree that, with respect to the initial RXH Partner Hospitals (totaling a minimum of four (4)), each such hospital
will be actively screening patients for enrollment into the Protocols within 30 days after the date that each such hospital obtains
IRB approval to participate in the program (the “Enrollment Date”).

 

		3.	Nuo Chapter 11.

 

		a.	Plan of Reorganization. Restorix understands that Nuo intends to reorganize its business and recapitalize its
balance sheet through consummation of a plan of reorganization whereby Nuo is required to raise $10,500,000 of committed common
equity capital by the effective date of the plan (“Nuo POR”). In the event Nuo is unsuccessful in raising the required
capital, then Nuo’s senior secured lender will receive 95% of the common equity in the reorganized debtor (“Lender
POR”). Given the proposed timeline to consummate either POR, it is unlikely that this Agreement will be fully performed prior
to consummation of a Nuo POR or Lender POR. Consequently Restorix has agreed to enter into this Agreement with Nuo, as a debtor
in possession, based upon Nuo’s assurance that this Agreement will be assumed in connection with consummation of the Nuo
POR. If the Agreement is not assumed upon consummation of the Nuo POR, it shall be conclusively deemed rejected and terminated
as of the date of consummation of the Nuo POR, which shall give rise to a termination fee of $150,000 (the “Termination Fee”)
payable by Nuo to Restorix within 5 business days of effective date of a Nuo POR. In the event of a Lender POR, if the agreement
is not assumed upon consummation of the Lender POR, it shall be conclusively deemed rejected and terminated as of the date of consummation
of the Lender POR but there will be no obligation of Nuo or the Lender to pay the Termination Fee. Regardless of whether Nuo is
in default of any of its obligations under the Agreement, Nuo and Restorix agree that the provisions of §365(b) of the Bankruptcy
Code regarding the cure of any defaults shall apply to Nuo’s assumption of this Agreement under, or in connection with, a
Nuo POR.

 

		b.	Administrative Expense Priority. All claims of Restorix arising under this Agreement, whether for Restorix’s
services hereunder, damages for Nuo’s breach of this Agreement (subject to the limitations in Section 12 hereof), or otherwise,
shall have priority in payment as administrative expense claims under §503(b) of the Bankruptcy Code. In addition, in the
event of a 363 Sale, the Successful Bidder shall be obligated to assume and pay Nuo’s obligations with respect to the Termination
Fee, if any, due to Restorix.

 

		4.	Term and Termination.

 

		a.	This Agreement shall commence on the Effective Date and shall continue for two years from the Effective Date (the “Initial
Term”). This Agreement may be extended one or more times with the mutual consent of both Parties (each such extension, an
“Extension Term,” and together with the Initial Term, the “Term”).

 

    	 	3	 

     

    

  

		b.	This Agreement can be terminated by either Party for material breach subject to a sixty (60) day cure period. Material breach
may include, but is not limited to, the failure of either Party to pay any required amounts due to the other Party under this Agreement.
Nuo hereby waives the protection of §362 of the Bankruptcy Code with respect to the exercise by Restorix of its right to terminate
this Agreement for material breach. For the elimination of all doubt, Restorix shall have the right to terminate this Agreement
for material breach without having to obtain relief from the automatic stay arising under §362 of the Bankruptcy Code from
the Bankruptcy Court or any other court.

 

		c.	In the event this Agreement is assigned by Nuo to a Successful Bidder under paragraph 3(b) hereof without Restorix’s
written consent, Restorix, for a period of sixty (60) days after receiving written notice of consummation of the 363 Sale, shall
have the right to terminate this Agreement for any or no reason.

 

		5.	Exclusivity.

 

		a.	During the Term Restorix will have site specific geographic exclusivity for usage of Aurix in connection with treatment of
patients in the Protocols within a thirty (30) mile radius of each RXH Partner Hospital, provided the following condition is maintained:

 

		i.	an individual RXH Partner Hospital meets the established enrollment goals detailed on Exhibit A for such RXH Partner Hospitals
at a minimum of 85% on a rolling two months basis. Should a site (or site cluster) fail to maintain the required minimum enrollment,
then such site will be allowed a 60 day cure period to return to 100% of the enrollment expectation for the 120 day trailing period.
Site level geographic exclusivity will be terminated, at Nuo’s sole option, if enrollment goals are not met over the cumulative
120 day period.

 

		b.	Nuo will not provide corporate exclusivity with any other wound management company operating in excess of 19 wound care facilities
for any similar arrangement during the Term provided the following condition is maintained:

 

		i.	no more than thirty percent (30%) of RXH Partner Hospitals can be failing to maintain their site specific geographic exclusivity
under paragraph 5(a) above or Nuo maintains the exclusive right to terminate any remaining portion of the Term’s corporate
exclusivity.

 

		c.	Existing Nuo CED sites (including those potential sites where active engagement has commenced with regard to potential participation
in the Protocols) will not be subject to the geographic exclusivity provisions in paragraph 5(a) above. Nuo and Restorix both agree
to mutually cooperate to resolve any issues about site and geographic exclusivity for the overall benefit of patient enrollment
into the Protocols.

 

    	 	4	 

     

    

  

		6.	Compensation.

 

		a.	Fees. Nuo shall pay to Restorix or the RXH Partner Hospital, as the case may be, a per patient data collection
(administrative) fee of $500 per patient. The data collection fee will be paid at the conclusion of the patient’s treatment
regimen once the accurate and complete set of required information has been delivered to the firm responsible for such data collection.
Such data collection fees will be invoiced to Nuo in the regular course and subject to normal payment procedures and terms. Restorix
agrees that they have no ownership of the data collected under the Protocols and will not publish any data collected under the
Protocols without prior Nuo consent.

 

		b.	Expenses. As outlined in paragraph 2(c)(iii) above, Nuo shall be responsible and pay for any IRB fees necessary
to conduct the Protocols and enroll patients. Additionally, Nuo shall pay Restorix a training cost stipend of $2,500 per site within
thirty (30) days of each of the RXH Partner Hospital’s respective Enrollment Date and subsequent training session.

 

		c.	Product Payment. For each Aurix System kit ordered, each RXH Partner Hospital shall pay Nuo in the normal course
and subject to standard payment terms the then current product price (which product price shall be $700 in 2016 and no greater
than $750 in the remainder of the Initial Term) which is reimbursed by CMS according to the Medicare Reimbursement Information
attached as Exhibit B.

 

		7.	Confidentiality.

 

		a.	In providing the Services, it may be appropriate and necessary for Restorix to have access to certain technical or business
information and material as well as information specifically deemed confidential or proprietary by third parties having business
relationships with Nuo (“Clients”). Examples of confidential information include, but are not limited to:

 

		i.	patients’ medical records including photographs, personal data, financial data, including any and all HIPAA protected
data;

 

		ii.	access to Clients’ financial records, software applications, databases, systems, technologies, devices, processes, formulas,
compositions, improvements, concepts, ideas, designs, methods, policies and procedures, investigation/audit results and potentially
limited employee information;

 

    	 	5	 

     

    

  

		iii.	any idea, proposal, plan, information, procedure, technique, formula, technology or method of operation, any written or oral
information of a proprietary nature, and any intellectual property owned by either Party or relating to the Client or Restorix’s
principals’ or affiliates’ business projects, operations, finances, activities or affairs, whether of a technical nature
or not (including trade secrets, know-how, processes and other technical or business information), and any proposed changes thereto;

 

		iv.	access to all information in subparagraphs (ii) and (iii) developed, acquired, owned or produced, or practiced by an affiliate
of Nuo, software program and/or documentation licensed by third parties;

 

		v.	customer or vendor lists; and

 

		vi.	any information disclosed by a Party and designated to be confidential.

 

		b.	Both Nuo and Restorix agree to hold all confidential information in strict confidence and shall not without the express prior
written permission of the other Party disclose any confidential information to third parties; use the confidential information
for any purpose other than to perform its obligations under this Agreement. The receiving Party should immediately notify the disclosing
Party if it learns, or has reason to believe, that any person who had access to confidential information violates or intends to
violate the terms of this section of the Agreement and shall cooperate in seeking injunctive relief against any such person.

 

		c.	Upon termination of this Agreement, or at any time upon the disclosing Party’s request, the Party with the confidential
information may request that all or a portion of the confidential data be returned or destroyed. The Parties may request written
confirmation that the data has been destroyed.

 

		d.	Nuo and Restorix will not disclose the terms and conditions of this Agreement to anyone other than their respective attorneys,
accountants and other professional advisors, except as required by applicable law or regulation provided either Party may choose
to publicize the existence of the Agreement with the consent of the other Party who shall have an opportunity to review and comment
on the disclosure. If legally required to be disclosed, then the Party requested to comply with such legal request shall provide
the other Party with reasonable notice of such requirement and a reasonable opportunity to react to such disclosure.

 

		e.	Both Nuo and Restorix agree that in event of any breach, the non-breaching Party will be entitled to injunctive relief against
such breach in court as well as other remedies legally available.

 

    	 	6	 

     

    

  

		f.	Both Nuo and Restorix may disclose confidential information to their officers, employees, attorneys and other representatives
who have an absolute need to know and are informed of and agree to be bound by the confidentiality obligations as set forth herein.
Restorix agrees to take all reasonable precautions to prevent disclosure of such confidential and proprietary information or materials
to third parties and not to use such information or materials without Nuo’s express written consent. These obligations of
confidentiality and non-use will continue beyond the Term but will cease to apply as to any specific portion of the Client’s
information or material which becomes available to the public through no fault attributable to any act or omission by Restorix.

 

		g.	In the event such confidential information is required to be disclosed by Restorix pursuant to regulatory or legal requirements,
Restorix agrees to immediately notify Nuo in writing in order to allow Nuo to seek a protective order or take other reasonable
and lawful actions to protect the Nuo’s rights prior to disclosure of the confidential information.

 

		h.	Subject to obtaining Nuo’s consent which shall not be unreasonably withheld, conditioned or delayed, Restorix shall have
the right to use Nuo’s name and/or trademark in its advertising, customer lists and marketing materials.

 

		8.	Assignment. Either Party may assign this Agreement with the written consent of the other Party, which
consent shall not be unreasonably withheld, conditioned or delayed; provided, however, that Restorix’s consent
shall not be necessary in connection with the transfer of this Agreement to a Successful Bidder in connection with a 363 Sale under
paragraph 3(b) hereof. Nothing herein contained shall in any way limit or otherwise restrict the rights of Restorix to demand that
Nuo and/or the Successful Bidder comply with the provisions of §365(f)
of the Bankruptcy Code including, without limitation, the requirement that all monetary defaults hereunder be cured and adequate
assurance of future performance be demonstrated, in connection with any 363 Sale.

 

		9.	Indemnification.

 

		a.	Nuo and Restorix hereby agree to indemnify, defend and hold harmless each other from and against any and all actual or threatened
claims, actions, damages, liabilities, costs and expenses, including without limitation reasonable attorney’s fees and expenses,
arising out of or connection with this Agreement, including, but not limited to:

 

		i.	the accuracy, validity or truthfulness of any of the representations made by the other Party in this Agreement or in any related
documents;

 

		ii.	the other Party’s failure to comply with any applicable law or regulation;

 

		iii.	third party claims of infringement of any patents, trade secrets, copy or trademarks, service marks, trade names or similar
proprietary rights alleged to have incurred with respect to content;

 

    	 	7	 

     

    

  

		iv.	the damage, loss or destruction of real or tangible personal property, to the extent that such death or bodily injury was caused
by the other Party’s gross negligence or willful misconduct; or

 

		v.	any damages incurred directly or by virtue of a claim made by a third party, in either case, arising out of a breach of a Party’s
representations, warranties, covenants or duties arising out of, or in connection with, this Agreement.

 

		b.	In addition, Restorix and Nuo shall be responsible for the actions of their employees, subcontractors, and clients whose activities
are either directly or indirectly, under or subject to the reasonable control of Restorix or Nuo, as the case may be.

 

		10.	Governing Law and Venue.  This Agreement will be deemed to have been executed in the State of Maryland
and will be governed by and construed in accordance with the laws of the State of Maryland, without reference to conflicts of law
principles. The Parties hereby consent to the exclusive jurisdiction of the courts located within the County in the State of the
defending Party for the purpose of any action or proceeding brought by either of them in connection with this Agreement.

 

		11.	Notices. Any notice required to be given hereunder shall be sufficient if in writing, and received by courier
service (with proof of delivery) or certified or registered mail (return receipt requested, first-class postage prepaid) at the
addresses of Nuo or Restorix set forth above, provided that either may change its address by notifying the other of such change.

 

		12.	Limitation of Liability. REGARDLESS OF WHETHER ANY REMEDY SET FORTH HEREIN FAILS OF ITS ESSENTIAL PURPOSE, IN
NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER IN CONTRACT, TORT, STRICT LIABILITY OR CAUSE OF ACTIONS OF ANY NATURE FOR ANY
INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, CONSEQUENTIAL OR RELIANCE, LOSS, DAMAGE OR EXPENSE, INCLUDING, WITHOUT LIMITATION, LOST
PROFITS OR LOSS OF USE IN REVENUES, WHETHER OR NOT EITHER PARTY WAS ADVISED, SHOULD HAVE KNOWN OR WAS AWARE OF THE POSSIBILITY
OF SUCH LOSS, DAMAGE OR EXPENSE ARISING OUT OF OR IN CONNECTION WITH ANY ACT OR OMISSION OF SUCH PARTY RELATING TO THE SUBJECT
MATTER OF THIS AGREEMENT. RESTORIX’S TOTAL LIABILITY OF ALL CLAIMS MADE UNDER THIS AGREEMENT SHALL NOT UNDER ANY CIRCUMSTANCE
EXCEED THE SUM TOTAL OF THE FEES PAID BY NUO TO RESTORIX UNDER THIS AGREEMENT FOR THE SERVICES. THE OBLIGATIONS OF THE PARTIES
UNDER THIS AGREEMENT RUN ONLY TO EACH OTHER AND NOT TO ANY OTHER PERSONS OR ENTITIES. NOTWITHSTANDING ANY OTHER TERMS AND CONDITIONS
OF THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY AS TO ANY THIRD PARTY INFORMATION OR PRODUCTS PROVIDED TO
EACH OTHER, ALL OF WHICH ARE PROVIDED, SOLD OR LICENSED “AS IS,” AND THE PARTIES AGREE TO LOOK SOLELY TO THE WARRANTIES
AND REMEDIES, IF ANY, PROVIDED BY THE THIRD PARTY. THE LIMITATIONS IN THIS SECTION DO NOT APPLY TO THE INDEMNIFICATION OBLIGATIONS
OF RESTORIX OR CLIENT FOR THIRD PARTY CLAIMS AS SET FORTH IN THE INDEMNIFICATION SECTION.

 

    	 	8	 

     

    

  

		13.	Representations and Warranties.

 

		a.	Restorix covenants, represents and warrants that:

 

		i.	the services to be performed hereunder will be performed in a commercially reasonable manner in accordance with the standards
generally prevailing in the industry;

 

		ii.	it has all necessary rights and authority to execute and deliver this Agreement and perform its obligations hereunder; and

 

		iii.	neither this Agreement nor Restorix’s performance of its obligations hereunder will place Restorix in breach of any other
contract or obligation and will not violate the rights of any third party.

 

		b.	Nuo covenants, represents and warrants that:

 

		i.	it has all necessary rights and authority to execute and deliver this Agreement and perform its obligations hereunder;

 

		ii.	neither this Agreement nor Nuo’s performance of its obligations hereunder will place Nuo in breach of any other contract
or obligation and will not violate the rights of any third party; and

 

		iii.	all information provided to Restorix is true and accurate.

 

		14.	Force Majeure. Neither Party shall be deemed in default or otherwise liable for any delay in or failure of its
performance under this Agreement (other than payment obligations) by any reason of any Act of God, fire, natural disaster, accident,
riot, act of government, strike or labor dispute, shortage of materials or supplies, failure of transportation or communication
of suppliers of goods or services, or any other cause beyond the reasonable control of such Party.

 

		15.	Obligations Pending the Effective Date. Once the condition set forth in paragraph 1(a) above has been satisfied:

 

		a.	Nuo shall:

 

		i.	on or before March 16, 2016 file a motion with the Bankruptcy Court seeking approval of this Agreement and entry of the Approval
Order (the “Motion”);

 

    	 	9	 

     

    

  

		ii.	provide Restorix with a reasonable opportunity to review and comment upon the Motion (or any other pleading to be filed by
Nuo in connection with the Motion) prior to it being filed with the Bankruptcy Court or its being served upon parties in interest;

 

		iii.	prosecute the Motion with reasonable diligence, in good faith, until the Bankruptcy Court grants or denies the relief requested
in the Motion (the “Decision”) and an appropriate order is entered by the Bankruptcy Court; and

 

		iv.	not enter into any agreement with any other person relating to the substance of this Agreement on the same or different terms
unless and until a Decision is obtained denying the relief requested in the Motion; and

 

		b.	Restorix shall reasonably co-operate with Nuo, as necessary, to obtain Bankruptcy Court approval of the relief requested in
the Motion; provided, however, that nothing herein contained shall obligate Restorix to agree to change any of the
terms of this Agreement and provided, further, however, that the execution by Restorix of an agreement substantially
similar to this Agreement with any other person, the effectiveness of which is conditioned on, among other things, such person
becoming the Successful Bidder, shall not be determined or deemed to be a violation by Restorix of this paragraph.

 

Notwithstanding any provision of Section 3 to
the contrary, if a Party has not breached any of its obligations under this Section 15, such Party may terminate this Agreement
without Bankruptcy Court approval or notice to any other party in interest, if the Effective Date does not occur by April 30, 2016,
by providing written notice to the other Party of the exercise by such Party of its right of termination.

 

		16.	General.

 

		a.	This Agreement contains the entire agreement and understanding by and between the Parties with respect to the subject matter
hereof, and no representations, promises, agreements or understandings, written or oral, not herein contained shall be of any force
or effect. No change or modification hereof shall be valid or binding unless the same is in writing and signed by both Parties.

 

		b.	This Agreement shall be binding upon, and shall inure to the benefit of Nuo and Restorix and their respective successors and
assignees.

 

		c.	Should any provision of this Agreement be held invalid by reason of any law, statute or regulation, or by a court of competent
authority, such provision shall be validly reformed so as to approximate the intent of the Parties as nearly as possible and, if
reformation is not possible, such provision shall be deemed divisible and deleted, but the remaining Agreement will not otherwise
be affected, and will remain in full force and effect.

 

    	 	10	 

     

    

  

		d.	The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting,
construing or enforcing any of the provisions of this Agreement.

 

		e.	This Agreement has been reviewed by the Parties and their respective attorneys, and the Parties have had a full opportunity
to negotiate the contents thereof. The Parties expressly waive any common law or statutory rule of construction that ambiguities
should be construed against the drafter of this Agreement, and agree that the language in all parts of this Agreement shall be
in all cases construed as a whole, according to its fair meaning.

 

		f.	No modification or waiver of any provision of this Agreement shall be valid or binding on either Party unless in writing and
signed by both Parties. No waiver of any term, right or condition under this Agreement on any one occasion or the failure of any
Party to insist upon strict performance of any of the terms and conditions hereof or failure or delay to exercise any rights provided
herein or by law shall be construed or deemed to be a waiver or continuing waiver of any such term, right or condition on any subsequent
occasion or a waiver of any other term, right or condition hereunder

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be
duly executed by duly authorized officers. Each person signing this Agreement represents and warrants that he or she is authorized
to execute this Agreement on behalf of the Party represented. This Agreement may be executed in duplicate originals, each of which
shall be considered the same document.

  

	RESTORIX HEALTH, INC.	 	NUO THERAPEUTICS, INC.

 

	By:	/s/ Steve McLaughlin	 	By:	/s/ David Jorden
	Name:  Steve McLaughlin	 	Name:  David Jorden
	Title:  Chief Executive Officer	 	Title:  Acting CEO/CFO

  

    	 	11	 

     

    

 

ACKNOWLEDGMENT
and Waiver

 

WHEREAS, on March
22, 2016, Restorix Health, Inc. (“Restorix” ), a Nevada corporation, with its principal offices at 455 Hamilton Avenue,
White Plains, NY 10601, and Nuo Therapeutics, Inc. (“Nuo”), a Delaware corporation, with its principal offices at 207A
Perry Parkway, Suite 1, Gaithersburg, Maryland 20877, entered into that certain Collaboration Agreement (the “Agreement”);

 

WHEREAS, on March
22, 2016, Nuo obtained approval from the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”)
to enter into the Agreement, by entry of that certain Order Authorizing And Approving The Debtor’s Entry Into The Collaboration
Agreement [Docket Entry No. 230] (the “Approval Order”); and

 

WHEREAS, Sections
1 and 15 of the Agreement provide that certain conditions must be satisfied or waived in order for the Agreement to become effective.

 

Restorix hereby: (i) waives
the condition in Section 1(c) of the Agreement that the Agreement cannot be deemed effective until the Approval Order becomes non-appealable;
and (ii) acknowledges and agrees that: (a) all of the conditions required for the Agreement to be effective have been satisfied;
(b) the Agreement is effective; and (c) March 22, 2016 is the “Effective Date” of the Agreement.

  

	RESTORIX HEALTH, INC.	 

 

	By:	/s/ Steve McLaughlin	 
	Name:  Steve McLaughlin	 
	Title:  Chief Executive Officer	 
	 	 
	Dated: March 22, 2016

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]